IntelliCell™ BioSciences Current and Planned Clinical Studies


IntelliCell BioSciences is planning to conduct several clinical studies in the following areas:

  • Osteoarthritis

    75% of those over the age of seventy exhibit detectable changes that are consistent with osteoarthritis. About 40-60% of subjects with radiological OA changes suffer from clinical symptoms such as pain, joint stiffness, and joint deformities. OA affects nearly 21 million people in the USA, accounting for 25% of visits to primary care physicians. It is estimated that 80% of the population will have radiographic evidence of OA by age 65 years, although only 60% of those will be symptomatic. Clinical manifestations of OA of the knee or the shoulder or both include pain in and around the joint, stiffness of the joint after rest, crepitating on motion and limited joint motion, among others.

    IntelliCell is planning an in-human clinical trial in late 2012 to study if the IntelliCell vascular fraction cells may demonstrate measurable benefits for patients suffering from this debilitating condition.

  • Sports Medicine Injuries

    Sports medicine injuries affect nearly all people who participate in active sports at one time or another. The more serious injuries, such as tears and sprains of the ligaments and tendons, may take many months to heal. Regenerative medicine, using autologous cell therapies, offers a promising therapy for faster recovery times and more complete healing from these types of injuries. IntelliCell is planning to work with top clinicians in treating injuries of this type.

  • Gingival Gum Regeneration

    Gingival recession or gum recession is a dental condition characterized by shrinking gums, which expose the roots of the teeth, potentially creating a variety of oral health problems. A patient may experience the onset of gingival recession at any time, with most cases starting between the late teens and the early 40's. Left untreated, gingival recession can have serious consequences, as the patient may start to lose dentin, an important part of the teeth, and the exposed roots may become tender, sore, or infected, causing immense pain. It is estimated that over 70% of the adult population may suffer from various gum diseases.

    In a pilot study conducted by Dr. Nicholas Toscano and published in The Journal of Implant and Advanced Clinical Dentistry, the IntelliCell vascular fraction cell therapy demonstrated positive outcomes with the subjects studied. IntelliCell is planning to follow this with additional studies late 2012.

  • Dermal treatment for burns and non-healing wounds

    Studies are demonstrating that the superficial injection of autologous vascular fraction cells into the skin is showing a clinically significant number of benefits. Many patients are seeing a reduction in lines and wrinkles as well as overall improvement in the tone, texture, and elasticity of the skin. IntelliCell believes that this therapy will demonstrate anti-aging benefits and will also show efficacy in the treatment of burns and scars. Further studies are being planned for this clinical application.

IntelliCell also plans to partner with other technology developers in the industry to examine the use of Vascular Fraction Cells in a number of clinically relevant areas such as:

  • Hair Loss in Men and Women
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • ALS Disease
  • Autism
  • Tinnitus
  • Bone fractures